RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN;
RECOMBINANT PROTEIN;
UNCLASSIFIED DRUG;
BMP2 PROTEIN, HUMAN;
BONE MORPHOGENETIC PROTEIN 2;
BONE GRAFT;
CONFLICT OF INTEREST;
DOSE RESPONSE;
DRUG APPROVAL;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
LETTER;
OSTEOLYSIS;
POSTOPERATIVE COMPLICATION;
PRIORITY JOURNAL;
RETROGRADE EJACULATION;
SPINE FUSION;
VERTEBRA BODY;
METHODOLOGY;
NOTE;
UNITED STATES;
BONE MORPHOGENETIC PROTEIN 2;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG APPROVAL;
HUMANS;
RECOMBINANT PROTEINS;
SPINAL FUSION;
UNITED STATES;
EID: 79952118273PISSN: 03622436EISSN: 15281159Source Type: Journal DOI: 10.1097/BRS.0b013e3181edf576Document Type: Letter
Complications related to osteobiologics use in spine surgery: A systematic review
Mroz TE, Wang JC, Hashimoto R, et al. Complications related to osteobiologics use in spine surgery: a systematic review. Spine (Phila Pa 1976) 2010; 35:S86-104.
US Food and Drug Administration, Department of Health and Human Services, Center for Devices and Radiological Health Available at Accessed January 31, 2010
Schultz D. US Food and Drug Administration, Department of Health and Human Services, Center for Devices and Radiological Health. InFUSE Bone Graft/LT-CAGE Lumbar Tapered Fusion Devices - P000058. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?num= P000058. Accessed January 31, 2010.
Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment
Re: Toth JM, Boden SD, Burkus JK, et al.
Smoljanovic T, Bojanic I, Bicanic G, et al. Re: Toth JM, Boden SD, Burkus JK, et al. Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment. Spine 2009;34:539-50.
Armstrong D, Burton TM. UCLAsurgeon didn't report payments. Wall St J. May 28, 2009. Available at: http://online.wsj.com/article/SB124348007018961469. html. Accessed February 11, 2010.